In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests. Acquisitions 2001: Completes acquisition of Ohio-based MedPlus, Inc. (), a healthcare technology company. 2002: Completes acquisition of Virginia-based American Medical Laboratories, Inc. (AML) and an affiliated company of AML, LabPortal, Inc., for approximately $500 million in cash. 2003: Completes acquisition of California-based Unilab Corporation () in a transaction valued at approximately $800 million. 2005: Completes acquisition of Lenexa, Kansas-based LabOne, Inc., which includes the Employer Solutions drug testing division and the ExamOne paramedical testing division, () for approximately $934 million. 2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests. 2006: Completes acquisition of Virginia-based Focus Diagnostics, Inc., an infectious and immunologic disease laboratory, for approximately $185 million in cash. 2007: Completes acquisition of Sweden-based Hemocue, a point-of-care diagnostic testing company. 2007: Acquires AmeriPath (and subsidiary Specialty Laboratories) from Welsh, Carson, Anderson & Stowe, becoming the leading provider of cancer diagnostic testing services. 2011: Acquires Athena Diagnostics from Thermo Fisher Scientific. 2011: Completes acquisition of Celera Corporation, a company that became famous by its sequencing of the Human Genome. 2014: Acquires Solstas Lab Partners Group (and subsidiaries). 2014: Acquires Summit Health, Inc. 2017: Acquires Cleveland HeartLab, Inc. 2018: Acquires U.S. laboratory services business of Oxford Immunotec. 2019: Acquires clinical laboratory services business of Boyce & Bynum Pathology Laboratories, a provider of diagnostic and clinical laboratory services in the Midwest. 2020: Acquires outreach laboratory service business of Memorial Hermann Health System, a non-for-profit health system in the Greater Houston region. Controversies Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical lab for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs. In 2018, Quest Diagnostics was among a number of US based labs linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening programme. Audits of the testing performed by Quest